CULLINAN THERAPEUTICS, INC. Convertible Debt
CULLINAN THERAPEUTICS, INC. (CGEM) had Convertible Debt of $0 as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ConvertibleDebt · last filed 2025-02-27
- 2024-12-31: Convertible Debt $0.00.
- 2024-09-30: Convertible Debt $0.00.
- 2024-06-30: Convertible Debt $0.00.
- 2024-03-31: Convertible Debt $0.00.
| Period end | Convertible Debt |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 |
| 2023-12-31 | $2.00M 10-K · filed 2025-02-27 |
| 2023-09-30 | $175.00K 10-Q · filed 2024-11-07 |
| 2023-06-30 | $175.00K 10-Q · filed 2024-08-08 |
| 2023-03-31 | $175.00K 10-Q · filed 2024-05-15 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |